- Bupa Platinum consultant
- Fee assured
- Awaiting verification
- Open Referral network
- Video and telephone consultations
- Home chemotherapy
Experienced specialist in the systemic treatment of lung, gastrointestinal malignancies and carcinoma unknown primary. Particular interest in immunotherapies and molecular targeted therapies. Underwent training in London and obtained CCT in medical oncology in 2009. My aim is to always provide patients a balanced and tailored approach to their situation, and to explore all options available.
Areas of interest
Lung cancer; mesothelioma; oesophageal/gastric cancer; pancreatic cancer; small bowel cancer; cholangiocarcinoma; colorectal cancer; neuroendocrine tumours; cancer of unknown primary (CUP).
Current NHS consultant posts held
Consultant Medical Oncologist West Suffolk Hospital
Use of targeted therapies in lung & GI cancer
Phase II/III studies
Cancer unknown primary
Football, cricket, tennis
ASCO merit award 2008
Lightowlers S & Patterson D. Mismanagment of malignant hypercalcaemia (2013). Clin Med February 1, 2013 vol. 13 no. 1 118
Patterson D.M, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ (2012): Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18(5):1415-25.
Patterson D. M, Aries J, Hyare H, Holder D, Rees, J and SM Lee (2011). Non-convulsive status epilepticus and leucoencephalopathy following high-dose methotrexate. J Clin Oncol. 2011 Jun 1;29(16):e459-61
Patterson D. M. and S. M. Lee (2010). Glucarpidase following high-dose methotrexate: update on development. Expert Opinion on Biological Therapy 10(1): 105-111
Whelan J, Patterson D. M, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M (2010). The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer. 54(3):350-4
Patterson, D. M., A. R. Padhani, et al. (2008). "Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy." Nat Clin Pract Oncol 5(4): 220-33.
Patterson, D. M., N. Murugaesu, et al. (2008). "A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites." International Journal of Gynecological Cancer 18(1): 43-50.
Patterson, D. M. and G. J. Rustin (2007). "Vascular Damaging Agents." Clin Oncol (R Coll Radiol) 19(6): 443-56.
- MBBS BSc UCL 1996
- FRCP RCP 2015
Reference number 4329563
Details of entry to specialist register
- CCT Medical Oncology , 2009
Affiliations / memberships
Association Cancer Physicians
European Society Medical Oncology (ESMO)
British Thoracic Oncology Group (BTOG)
- BMI St Edmunds Hospital, IP33 2AA
- 18:00 - 20:00
- 01284 713195
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (1-5)
St Edmunds Hospital (1-5)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (1-5)